Institutional members access full text with Ovid®

Share this article on:

Use of Bone Morphogenetic Protein in the Lumbar Spine

Schroeder, Gregory D. MD; Hsu, Wellington K. MD

Contemporary Spine Surgery: March 2014 - Volume 15 - Issue 3 - p 1–8
doi: 10.1097/01.CSS.0000444303.99362.28
Article

Dr. Schroeder is Resident, Department of Orthopaedic Surgery, and Dr. Hsu is Professor, Department of Orthopaedic Surgery and Neurosurgery, Northwestern University Feinberg School of Medicine, 676 N. Saint Clair, Suite 1350, Chicago, IL 60611; E-mail: whsu@nmff.org.

All faculty and staff in a position to control the content of this CME activity and their spouses/life partners (if any) have disclosed that they have no financial relationships with, or financial interests in, any commercial organizations related to this CME activity.

The authors have disclosed that the U.S. Food and Drug Administration has not approved the use of rhBMP-2 in the lumbar spine unless it is used in an anterior lumbar interbody fusion with a specific interbody spacer as discussed in this article. Please consult the product's labeling for approved information.

Lippincott Continuing Medical Education Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Lippincott Continuing Medical Education Institute designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. To earn CME credit, you must read the CME article and complete the quiz and evaluation assessment survey on the enclosed form, answering at least 70% of the quiz questions correctly. This activity expires on February 28, 2015.

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website